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To help overcome the bottlenecks that limit the development of diagnostic and therapeutic
products, academic and industrial researchers, patient organizations and charities, and regulatory
and funding institutions should redefine the basis for sharing the knowledge collected in large-scale
clinical and experimental studies.
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Advances in biological and medical research and their
translation into diagnostic, prognostic and therapeutic tools
are relying increasingly on partnerships between the aca-
demic (government and university) and industrial (biotech-
nology, pharmacy and technology) sectors, with essential
participation and support from patient organizations and
charities. Despite these concerted efforts and the promises of
genomics and systems biology, over the past two decades the
cost of research and development has continuously esca-
lated, while the number of truly novel drugs coming to
market has constantly declined. To a large extent, this has
been addressed in the private sector through mergers and
outsourcing, with downsizing of the research and
development workforce. These trends cannot be sustained
further as they threaten the economic viability of the
healthcare system worldwide. At a time of a global crisis, it is
crucial to identify how we can overcome these hurdles. I
argue here that we should look again at how knowledge can
be shared between all the stakeholders, redefining the
frontier between what can be the subject matter of valuable
intellectual property rights and what is the basic knowledge
that should be made freely available to all.
This is not a new issue. It was hotly debated at the beginning
of the Human Genome Project (HGP), and for its entire
duration in relation to competition between the public and
private sectors. I suggested early on that the nucleic acid
sequences collected on a genome scale should be considered
as elements of description insufficient to warrant property
rights by themselves in the absence of a genuine invention
and should thus be placed in the public domain [1]. A similar
attitude was taken by the participants of the HGP in 1996, as
expressed in the ‘Bermuda rules’ [2], with the result that the
openly accessible reference human genome sequence is now
the common basis for current research. These proposals
contributed to the ‘Universal declaration on the human
genome and human rights’ adopted by the United Nations
and its Educational, Scientific and Cultural Organization
(UNESCO) in 1997-1998, which stated about the human
genome: “In a symbolic sense, it is the heritage of
humanity”, and “The human genome in its natural state shall
not give rise to financial gains.” The issue was, and remains
to a large extent, how best to balance general and particular
interests to sustain basic research while promoting efficient
healthcare product development. This has been discussed
extensively on ethical, legal and social grounds, and the
counterproductive underuse of scarce resources when they
are protected by excessive intellectual property rights (the
tragedy of the ‘anticommons’ [3]) has been pointed out;
these discussions have led to proposals to establish patent
pools to facilitate development of diagnostic tests [4].
The recent advent and rapid development of new genera-
tions of very-high-throughput DNA sequencing methodsmakes it now possible to foresee that in the next few years
the sequencing and assembly of thousands of human
genomes (and transcriptomes) will be achievable at a cost of
$1,000 each or less, which is a projected decrease of almost a
million-fold in less than ten years. Without the availability of
the reference sequence, such astonishing advances would
not be possible. With each sequencing run delivering infor-
mation on the scale of the entire GenBank, it is clear that
data quality assessment and analysis are becoming the
limiting steps, beyond the capability of single individuals or
groups. Similar trends can be anticipated for proteins and
metabolites when reference proteomes and metabolomes
also become available in the coming years. Public electronic
repositories for these large-scale datasets, together with
standards and open access publications for their description,
have been important developments in the past decade for
ensuring that they become available for further studies.
However, despite requirements by prominent journals and
funding agencies for submission of primary data as a
condition for publication and financial support, recent
surveys indicate variable compliance with these rules in both
academia and industry [5]. There is clearly room for
significant improvements in this area if researchers are to
take the best advantage of the large datasets produced.
The same issues of data quality and availability are becom-
ing prominent in the assembly of ever-increasing patient
cohorts for the purpose of clinical trials and genome-wide
genetic association studies, now often reaching tens of
thousand of samples [6]. Great efforts have been made,
initially in developed countries, to establish standards of
good practice for informed consent, clinical trial registration
and sample collection and storage in biobanks, and these are
now being enforced in newly industrialized countries such as
China and India. Although these are welcome developments,
much also remains to be done to ensure that these essential
resources are used to the best advantage of the patients
themselves, and to use genomics and bioinformatics to
sustain the development of systems biology and medicine
[7]. The issues are many and complex, given the sensitive
status of human material with respect to legal rules and
practices that can vary substantially from country to
country. International harmonization of health regulations
and intellectual property rights is ongoing; this is necessary
but insufficient to overcome the major bottlenecks in the
development of healthcare products, and it will take time to
mature and adapt to the rapid pace of technology develop-
ment. All stakeholders should work together to identify
topics and areas in which joint actions would improve the
situation significantly in the short term.
I would like to suggest that one such topic is the status and
availability of large amounts of underexploited experimental
and clinical data in public and private laboratories. In many
cases, these existing databases have been developed for a
specific purpose, with a focus on a small number of
biological elements. With the shift from targeted to global
analyses, most of the data collected are not exploited at all,
although they could be relevant in another context. It must
be recognized that the high potential value of these datasets
relies to a large extent on the quality of the biological and
clinical annotations, which becomes significant only if the
experimental data are properly collected and described.
When that is the case, the added value will come from
provision of the combined data for further analysis by other
experts addressing related and complementary questions.
Recognizing this as a topic for sharing of knowledge between
academic and industrial partners and establishing data
warehouses with agreed open access rules would be a
significant step in this direction. It will hopefully be
discussed intensely in the columns of Genome Medicine.
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